• HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IL-28A protein

Activity

0.01-0.06 ng/mL

Species Reactivity

human

Purity

>95%

Cat No : HZ-1235

Print datasheet

Synonyms

Cytokine Zcyto20, IFN lambda 2, IFNL2, IL 28A, IL28, IL-28, IL28A, IL-28A, Interferon lambda 2, Interleukin 28A, ZCYTO20



Technical Specifications

GeneID 282616
Species Human
Expression HEK293
Activity 0.01-0.06 ng/mL
Purity >95%
Endotoxin<1 EU/μg
Accession NumberQ8IZJ0
Molecular Mass 22 kDa reduced, 19 and 35 kDa non-reduced, monomer, non-glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix.

Background

IL28A is a type III IFN, which shares many of the biological effects of type I IFNs but may have fewer side effects due to a more selective receptor distribution. It interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha (IL28RA). IL28A is believed to play a significant role in the antiviral immune defense in the intestinal epithelium (PMID: 20712453;12469119;16539846).

Synonyms

Cytokine Zcyto20, IFN lambda 2, IFNL2, IL 28A, IL28, IL-28, IL28A, IL-28A, Interferon lambda 2, Interleukin 28A, ZCYTO20

Publications

SpeciesTitle

Antiviral Res

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.

Authors - Takashi Nishiyama
human

J Virol Methods

Screening of novel drugs for inhibiting hepatitis E virus replication.

Authors - Takashi Nishiyama